Adiposity and metabolic health in Asian populations: an epidemiological study using dual-energy x-ray absorptiometry in Singapore.


Journal

The lancet. Diabetes & endocrinology
ISSN: 2213-8595
Titre abrégé: Lancet Diabetes Endocrinol
Pays: England
ID NLM: 101618821

Informations de publication

Date de publication:
29 Aug 2024
Historique:
received: 21 02 2024
revised: 02 07 2024
accepted: 02 07 2024
medline: 2 9 2024
pubmed: 2 9 2024
entrez: 1 9 2024
Statut: aheadofprint

Résumé

Type 2 diabetes, cardiovascular disease, and related cardiometabolic disturbances are increasing rapidly in the Asia-Pacific region. We investigated the contribution of excess adiposity, a key determinant of type 2 diabetes and cardiovascular risk, to unfavourable cardiometabolic profiles among Asian ethnic subgroups. The Health for Life in Singapore (HELIOS) Study is a population-based cohort comprising multiethnic Asian men and women living in Singapore, aged 30-84 years. We performed a cross-sectional analysis of data from individuals who had assessment of body composition by dual-energy x-ray absorptiometry and metabolic characterisation. In a subset of participants on no medication for type 2 diabetes, hypertension, and hypercholesterolaemia, we tested the relationship of BMI and visceral fat mass index (vFMI) with cardiometabolic phenotypes (glycaemic indices, lipid levels, and blood pressure), disease outcomes (type 2 diabetes, hypercholesterolaemia, and hypertension), and metabolic syndrome score with multivariable regression analyses. Between April 2, 2018, and Jan 28, 2022, 10 004 individuals consented to be part of the HELIOS cohort, of whom 9067 were included in the study (5404 [59·6%] female, 3663 [40·4%] male; 6224 [68·6%] Chinese, 1169 [12·9%] Malay, 1674 [18·5%] Indian; mean age 52·8 years [SD 11·8]). The prevalence of type 2 diabetes, hypercholesterolaemia, and hypertension was 8·2% (n=744), 27·2% (n=2469), and 18·0% (n=1630), respectively. Malay and Indian participants had 3-4-times higher odds of obesity and type 2 diabetes, and showed adverse metabolic and adiposity profiles, compared with Chinese participants. Excess adiposity was associated with adverse cardiometabolic health indices including type 2 diabetes (p<0·0001). However, while vFMI explained the differences in triglycerides and blood pressure between the Asian ethnic groups, increased vFMI did not explain higher glucose levels, reduced insulin sensitivity, and increased risk of type 2 diabetes among Indian participants. Visceral adiposity is an independent risk factor for metabolic disease in Asian populations, and accounts for a large fraction of type 2 diabetes cases in each of the ethnic groups studied. However, the variation in insulin resistance and type 2 diabetes risk between Asian subgroups is not consistently explained by adiposity, indicating an important role for additional mechanisms underlying the susceptibility to cardiometabolic disease in Asian populations. Nanyang Technological University-the Lee Kong Chian School of Medicine, National Healthcare Group, and National Medical Research Council, Singapore.

Sections du résumé

BACKGROUND BACKGROUND
Type 2 diabetes, cardiovascular disease, and related cardiometabolic disturbances are increasing rapidly in the Asia-Pacific region. We investigated the contribution of excess adiposity, a key determinant of type 2 diabetes and cardiovascular risk, to unfavourable cardiometabolic profiles among Asian ethnic subgroups.
METHODS METHODS
The Health for Life in Singapore (HELIOS) Study is a population-based cohort comprising multiethnic Asian men and women living in Singapore, aged 30-84 years. We performed a cross-sectional analysis of data from individuals who had assessment of body composition by dual-energy x-ray absorptiometry and metabolic characterisation. In a subset of participants on no medication for type 2 diabetes, hypertension, and hypercholesterolaemia, we tested the relationship of BMI and visceral fat mass index (vFMI) with cardiometabolic phenotypes (glycaemic indices, lipid levels, and blood pressure), disease outcomes (type 2 diabetes, hypercholesterolaemia, and hypertension), and metabolic syndrome score with multivariable regression analyses.
FINDINGS RESULTS
Between April 2, 2018, and Jan 28, 2022, 10 004 individuals consented to be part of the HELIOS cohort, of whom 9067 were included in the study (5404 [59·6%] female, 3663 [40·4%] male; 6224 [68·6%] Chinese, 1169 [12·9%] Malay, 1674 [18·5%] Indian; mean age 52·8 years [SD 11·8]). The prevalence of type 2 diabetes, hypercholesterolaemia, and hypertension was 8·2% (n=744), 27·2% (n=2469), and 18·0% (n=1630), respectively. Malay and Indian participants had 3-4-times higher odds of obesity and type 2 diabetes, and showed adverse metabolic and adiposity profiles, compared with Chinese participants. Excess adiposity was associated with adverse cardiometabolic health indices including type 2 diabetes (p<0·0001). However, while vFMI explained the differences in triglycerides and blood pressure between the Asian ethnic groups, increased vFMI did not explain higher glucose levels, reduced insulin sensitivity, and increased risk of type 2 diabetes among Indian participants.
INTERPRETATION CONCLUSIONS
Visceral adiposity is an independent risk factor for metabolic disease in Asian populations, and accounts for a large fraction of type 2 diabetes cases in each of the ethnic groups studied. However, the variation in insulin resistance and type 2 diabetes risk between Asian subgroups is not consistently explained by adiposity, indicating an important role for additional mechanisms underlying the susceptibility to cardiometabolic disease in Asian populations.
FUNDING BACKGROUND
Nanyang Technological University-the Lee Kong Chian School of Medicine, National Healthcare Group, and National Medical Research Council, Singapore.

Identifiants

pubmed: 39217997
pii: S2213-8587(24)00195-5
doi: 10.1016/S2213-8587(24)00195-5
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.

Déclaration de conflit d'intérêts

Declaration of interests JC receives support for attending meetings and travel from Lee Kong Chian School of Medicine Strategic Academic Initiative and National Medical Research Council Singapore Translational Research Investigator Award and President's Chair in Cardiovascular Epidemiology. JC is Programme Director for Population and Global Health Programme at Lee Kong Chian School of Medicine, and Chief Scientific Officer at Precision Health Research, Singapore. JN receives research funding from Astra Zeneca. JL participates in the advisory board of Boehringer Ingelheim and is a council member of National Council Against Drug Abuse, Singapore. BLCC receives honorarium for obesity-related presentations and participates in the advisory boards of Novo Nordisk, Abbott Nutrition, and DKSH, and all honoraria were paid to Khoo Teck Puat Hospital, Singapore. All other authors declare no competing interests.

Auteurs

Theresia Mina (T)

Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.

Wubin Xie (W)

Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.

Dorrain Yanwen Low (DY)

Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.

Xiaoyan Wang (X)

Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.

Benjamin Chih Chiang Lam (BCC)

Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Integrated Care for Obesity & Diabetes, Khoo Teck Puat Hospital, Singapore.

Nilanjana Sadhu (N)

Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.

Hong Kiat Ng (HK)

Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.

Nur-Azizah Aziz (NA)

Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.

Terry Yoke Yin Tong (TYY)

Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.

Swat Kim Kerk (SK)

Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.

Wee Lin Choo (WL)

Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.

Guo Liang Low (GL)

Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.

Halimah Ibrahim (H)

Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.

Liming Lim (L)

Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.

E Shyong Tai (ES)

Saw Swee Hock School of Public Health, National University of Singapore, Singapore.

Gervais Wansaicheong (G)

Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Department of Diagnostic Radiology, Tan Tock Seng Hospital, Singapore.

Rinkoo Dalan (R)

Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Department of Endocrinology, Tan Tock Seng Hospital, Singapore.

Yik Weng Yew (YW)

Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Research Division, National Skin Centre, Singapore.

Paul Elliott (P)

Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.

Elio Riboli (E)

Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.

Marie Loh (M)

Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.

Joanne Ngeow (J)

Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Division of Medical Oncology, National Cancer Centre, Singapore.

Eng Sing Lee (ES)

Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; National Healthcare Group Polyclinic, Singapore.

Jimmy Lee (J)

Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; North Region, Institute of Mental Health, Singapore.

James Best (J)

Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Melbourne Medical School, University of Melbourne, Parkville, VIC, Australia.

John Chambers (J)

Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK. Electronic address: john.chambers@ntu.edu.sg.

Classifications MeSH